Payment overview · 2025
General Payments
$13,556.38
154 reported records · 10 companies
Healthcare provider profile · identity verified
Ryan Patrick Lydon, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · ROCHESTER, NY · NPI 1407297260
Verified facts
What the public records show
CMS Open Payments records show Ryan Patrick Lydon, M.D. received $13,556.38 in general payments during 2025 across 154 reported records.
Medtronic, Inc. accounted for 85.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$11,544.06 | 85.2% | 133 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $672.55 | 5.0% | 5 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $433.84 | 3.2% | 3 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $212.62 | 1.6% | 2 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $173.15 | 1.3% | 5 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $145.39 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $138.48 | 1.0% | 1 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $133.24 | 1.0% | 2 | 2025 |
| Contego Medical, Inc | Unresolved — no canonical attribution shown | $70.05 | 0.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $33.00 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,603.00 | 148 |
| Travel and Lodging | $5,593.38 | 5 |
| Consulting Fee | $360.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $3,378.73 | 64 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $889.72 | 11 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $834.88 | 23 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $360.00 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $301.98 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $300.93 | 2 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $212.62 | 2 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $206.01 | 3 | 2025 |
Source payment records
|
|||||
| EVERCROSS Normalized: evercross |
Device | Medtronic, Inc. | $177.07 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $167.71 | 3 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $147.63 | 3 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $145.39 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $138.48 | 1 | 2025 |
Source payment records
|
|||||
| HELI-FX ENDOANCHOR SYSTEM Normalized: heli fx endoanchor system |
Device | Medtronic, Inc. | $137.26 | 1 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $133.24 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $132.91 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $132.91 | 1 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $108.54 | 2 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $97.86 | 3 | 2025 |
Source payment records
|
|||||
| RELAY PLUS THORACIC STENT-GRAFT SYSTEM Normalized: relay plus thoracic stent graft system |
Device | Terumo Medical Corporation | $87.95 | 1 | 2025 |
Source payment records
|
|||||
| VISI-PRO Normalized: visi pro |
Device | Medtronic, Inc. | $51.13 | 2 | 2025 |
Source payment records
|
|||||
| MVP Normalized: mvp |
Device | Medtronic, Inc. | $41.90 | 2 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $37.32 | 3 | 2025 |
Source payment records
|
|||||
| AffiX Normalized: affix |
Device | Globus Medical, Inc. | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| GLIDEWIRE Normalized: glidewire |
Device | Terumo Medical Corporation | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $10.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 25 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,556.38 · 154 records | Medtronic, Inc. | ABRE, AZUR CX DETACHABLE, AffiX, CHOCOLATE PTA BALLOON CATHETER, CLOTTRIEVER BOLD CATHETER, CONCERTOTM, CT THROMBECTOMY SYSTEM KIT, ENDURANT IIS, ESPRIT, EVERCROSS, FLOWTRIEVER CATHETER, S, GLIDESHEATH SLENDER, GLIDEWIRE, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Conformable Thoracic Endoprosthesis, HAWKONE, HELI-FX ENDOANCHOR SYSTEM, IMPEDE EMBOLIZATION PLUG, IN.PACT ADMIRAL, IN.PACT AV, Indigo System, METACROSS OTW, MVP, PROTEGE RX, Product in Development, R2P MISAGO, RELAY PLUS THORACIC STENT-GRAFT SYSTEM, TREO ABDOMINAL STENT-GRAFT SYSTEM, TURBOHAWK, VISI-PRO | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error